Critical Path Institute Awards $249,719 Grant to Odylia Therapeutics to Advance Gene Therapy for USH1C-Associated Vision Loss

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text css=""]TUCSON, Arizona., May 20, 2026 — Critical Path Institute® (C-Path) today announced the award of a $249,719 research grant to Odylia Therapeutics, a nonprofit biotechnology organization based in Atlanta. The awarded program and Odylia are led by...